WallStreetZenWallStreetZen

NASDAQ: INDV
Indivior Pharmaceuticals Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Indivior Pharmaceuticals earnings were $355.0M for the trailing 12 months ending Jun 30, 2026, with 238.8% growth year over year. The latest INDV earnings report on Jun 30, 2026 announced Q2 2026 earnings of $122.0M, up 37.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, INDV reported annual earnings of $210.0M, with 2,900% growth.

INDV past earnings growth

How has INDV's earnings growth performed historically?

Company
238.82%
Industry
103.37%
Market
91.1%
INDV's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
INDV's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
INDV's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

INDV earnings history

Current Revenue
$1.3B
Current Earnings
$355.0M
Current Profit Margin
26.7%

INDV Return on Equity

Current Company
-216.1%
Current Industry
1.7%
Current Market
28.8%
INDV's Return on Equity (-216.1%)... subscribe to Premium to read more.
High Return on Equity Performance

INDV Return on Assets

Current Company
28.1%
Current Industry
4%
INDV is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when INDV announces earnings.

INDV Return on Capital Employed

Current Company
115.07%
Current Industry
9.5%
INDV has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

INDV vs Pharmaceutical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
INDV$437.00M$355.00M+238.82%$2.88
AMRX$564.97M$157.36M+48.17%$0.50
SUPN-$7.02M-$109.89MN/A-$1.92
RGCN/AN/AN/AN/A
LNTH$471.29M$275.31M+74.04%$4.22
View Top Pharmaceutical Stocks

Indivior Pharmaceuticals Earnings Reports & History FAQ

What were Indivior Pharmaceuticals's earnings last quarter?

On INDV's earnings call on Aug 4, 2026, Indivior Pharmaceuticals (NASDAQ: INDV) reported Q2 2026 earnings per share (EPS) of $1.02, up 580% year over year. Total INDV earnings for the quarter were $122.00 million. In the same quarter last year, Indivior Pharmaceuticals's earnings per share (EPS) was $0.15.

If you're new to stock investing, here's how to buy Indivior Pharmaceuticals stock.

Is Indivior Pharmaceuticals profitable or losing money?

As of the last Indivior Pharmaceuticals earnings report, Indivior Pharmaceuticals is currently profitable. Indivior Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $355.00 million, a 228.7% increase year over year.

What was INDV's earnings growth in the past year?

As of Indivior Pharmaceuticals's earnings date in Aug 4, 2026, Indivior Pharmaceuticals's earnings has grown 238.82% year over year. This is 135.46 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 103.37%. INDV earnings in the past year totalled $355.00 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.